Skip to main content
John Buse, MD, Endocrinology, Chapel Hill, NC

JohnBBuseMD

Endocrinology Chapel Hill, NC

Diabetes, Obesity

Professor of Medicine, University of North Carolina School of Medicine

Dr. Buse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Buse's full profile

Already have an account?

  • Office

    100 Eastowne Dr
    Pod 3B
    Chapel Hill, NC 27514
    Phone+1 984-974-2950
    Fax+1 984-974-2924

Summary

  • Diabetes mellitus

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1992
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1986 - 1988
  • Duke University
    Duke UniversityPh.D., Physiology/Immunology, 1979 - 1986
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1986
  • Dartmouth College
    Dartmouth CollegeAB, Biochemistry, Cum Laude, 1976 - 1979

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1994 - 2025
  • IL State Medical License
    IL State Medical License 1986 - 1996
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • Best Doctors Best Doctors
  • America's Top Doctors Castle Connolly, 2010-2019
  • �Highly Cited Researchers� in �Clinical Medicine� Thomson Reuters, 2014-2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Improved Time in Range and Glycemic Variability with Sotagliflozin in Combination with Insulin in Adults with Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous ...  
    Jake A Kushner, John B Buse, Satish K Garg, Darren K McGuire, Diabetes Care
  • Lower Rates of Cardiovascular Events and Mortality Associated with Liraglutide Use in Patients Treated with Basal Insulin – A DEVOTE Subanalysis (DEVOTE 10)  
    John B Buse, Darren K McGuire, Richard E Pratley, Diabetes, Obesity and Metabolism
  • Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes  
    Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swense..., Diabetes Care, 1/1/2019
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Lectures

  • For Debate: A Reasonable A1C Goal for Many Nonpregnant Adults is <7% (53 mmol/mol) 
    ENDO 2019 - New Orleans, LA - 3/23/2019
  • Neoplasms Reported with Liraglutide or Placebo in People with Type 2 Diabetes: Results from the LEADER Randomized Trial 
    Chapel Hill, NC - 6/15/2014
  • Duke Regional Diabetes Symposium 2012 
    Duke University School of Medicine, Kannapolis, North Carolina - 7/13/2012

Other

  • Consensus Development Conference on Pramlintide in the Management of Type 1 and Type 2 Diabetes 
    Hirsch IB, Blonde L, Buse J, Close K, Edelman SV, Peters A, Valentine V, Wysham C, Garg S, The Diabetes Education Group
    Lakeville, CT - 1/1/2006
  • A practical approach to the management of type 2 diabetes in the context of cardiovascular risk. 
    Buse JB, Henry RR, Pri-Med in Practice
    Boston, MA - 1/1/2006
  • Management of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in Adults. 
    JB Buse, M Menke, TS Sisca, Scherer Clinical Communication
    1/1/2005
  • Join now to see all

Authored Content

  • Management of Type 1 Diabetes with a Very Low–Carbohydrate Diet: A Word of CautionAugust 2018

Press Mentions

  • Intensive Blood Pressure Control Benefits People with Type 2 Diabetes Too
    Intensive Blood Pressure Control Benefits People with Type 2 Diabetes TooNovember 16th, 2024
  • Newsworthy from the School of Medicine, Week of August 16 – August 22
    Newsworthy from the School of Medicine, Week of August 16 – August 22August 21st, 2024
  • Are New Weight Loss Drugs Really an Obesity ‘Game Changer’?
    Are New Weight Loss Drugs Really an Obesity ‘Game Changer’?January 24th, 2023
  • Join now to see all

Grant Support

  • Genome-Wide Association Study Of Accord Lipid TrialNational Heart, Lung, And Blood Institute2012
  • Clinical Trial: Action To Control Cardiovascular Risk In Diabetes Trial (ACCORD)National Center For Research Resources2008
  • NMR &Chemical Lipid Analysis In Patients With Type 2 DiabetesNational Center For Research Resources2007
  • Action To Control Cardiovascular Risk In Diabetes Trial (ACCORD)National Center For Research Resources2007
  • Zenarestat (Ci 1014) In Treatment Of Diabetic NeuropathyNational Center For Research Resources1999–2002
  • Trial Comparing HOE 901 &Nph Human Insulin Subjects W/ Type I DiabetNational Center For Research Resources1999–2002
  • Oral Gi262570x In Patients W/ Type 2 Diabetes MellitusNational Center For Research Resources1999–2002
  • Niaspan In Type 2 Diabetic Patients W/ DyslipidemiaNational Center For Research Resources1999–2002
  • Metformin/Glyburide As 1st LINE Therapy In Type 2 DiabetesNational Center For Research Resources1999–2002
  • Insulin Delivery Using New Lilly 3 0 ML Disposable Pen DeviceNational Center For Research Resources1999–2002
  • 570x As Monotherapy For Subjects W/ Type 2 DiabetesNational Center For Research Resources1999–2002
  • Efficacy Trial Of Voglibose (A)-1128 2 MG In Type II DiabetesNational Center For Research Resources1998–2002
  • Comparison Of Human Insulin Analogue X14 In Type I DiabetesNational Center For Research Resources1998–2002
  • Clinical Trial Comparing HOE 901 Insulin With NPH Human Insulin Type INational Center For Research Resources1998–2002
  • Clinical Trial Comparing HOE 901 Insulin With NPH Human Insulin In NIDDMNational Center For Research Resources1998–2002
  • Atorvastatin As Secondary Prevention Of Coronary Heart DiseaseNational Center For Research Resources1998–2002
  • 54 Week OPEN Label Assessment Of Safety/Efficacy Of Atorvastatin/SimvastatinNational Center For Research Resources1998–2002
  • 24-Week Double-Blind Study Of TroglitazoneNational Center For Research Resources1998–2002
  • Troglitazone VS Placebo In Noninsulin Dependent Diabetes MellitusNational Center For Research Resources1997–2002
  • Pimagedine In Patient With Type II Diabetes And Overt Diabetic NephropathyNational Center For Research Resources1997–2002
  • Aminoguanidine In Diabetic Patients With Overt Diabetic NephropathyNational Center For Research Resources1996–2002
  • Troglitazone W/Sulfonylurea Or PLUS Metformin In NIDDMNational Center For Research Resources2000
  • Rosiglitazone W/ Glyburide &Metformin In NIDDM PTSNational Center For Research Resources2000
  • Pimagedine In Diabetic PTS W/ Overt Diabetic NephropathyNational Center For Research Resources2000
  • Glucagon Receptor Antagonist BAY 27-9955 In NIDDMNational Center For Research Resources2000
  • Gennid--Genetics Of Non-Insulin-Dependent DiabetesNational Center For Research Resources2000
  • Effects Of Subcutaneous Administrated Ac2993 In NIDDMNational Center For Research Resources2000
  • Effec Of A-100 On Glycemic Control In Overweight NIDDMNational Center For Research Resources2000
  • Atorvastatin As Prevention Of CHD In PTS W/ NIDDMNational Center For Research Resources2000
  • Atorvastatin As Compared To Simvastatin In DyslipidemiaNational Center For Research Resources2000
  • Akesis PRO Health PAK (Dietary Supplement) In NIDDMNational Center For Research Resources2000
  • Diabetes Prevention Trial Of Type I DiabetesNational Center For Research Resources1997–1999
  • D-Chiro-Inositol, Pinitol And Myoinositol Concentrations In Diabetic PatientsNational Center For Research Resources1997–1999
  • Protect-Procose (Acarbose Tablets)--DiabetesNational Center For Research Resources1997
  • Troglitazone (Ci-991) In Patients With NIDDMNational Center For Research Resources1996–1997
  • Metabolic And Genetic Screening Of Families With DiabetesNational Center For Research Resources1996–1997
  • Double Blind Study Of Troglitazone (Ci-991)National Center For Research Resources1996

Committees

  • Co-chair, member, CTSA Program Steering Committee 2018 - Present

Research History

  • Director, Diabetes CenterOur group’s research efforts focus in clinical trials, epidemiology and translational efforts towards application of novel ideas to clinical practice.1994 - Present

Professional Memberships